SWOG 1815: Phase III Trial of First-line Gemcitabine/Cisplatin ± Nab-Paclitaxel for Advanced Biliary Tract Cancers

Source: CCO Independent Conference Highlights of the 2023 ASCO Gastrointestinal Cancers Symposium*
Download Slideset
January 19-21, 2023; San Fransico, California
The phase III SWOG 1815 trial showed that adding nab-paclitaxel to first-line gemcitabine/cisplatin did not significantly prolong OS or PFS and was associated with increased severe hematologic toxicity in advanced biliary tract cancers.
Format: Microsoft PowerPoint (.ppt)
File Size: 205 KB
Released: January 26, 2023

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Incyte Corporation
Merck Sharp & Dohme Corp.
Seagen Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings